The global preimplantation genetic diagnosis market worth $545.8 Million by 2030, growing at a CAGR of 10.2%

Preimplantation genetic diagnosis (PGD) is a genetic testing method used to identify genetic defects in embryos produced through in-vitro fertilization (IVF) before pregnancy. This procedure is performed on those who are at risk of passing genetic disease or chromosome abnormality to their children. Preimplantation genetic diagnosis is most frequently used in assisted reproduction technologies for detection of chromosome aneuploidy from structural chromosome rearrangements. This method selects genetically healthy embryo for transfer in uterus. The whole diagnosis process includes test (biopsy), preparation of the genetic material (amplification & DNA isolation), analysis and result. The whole procedure is performed before the implantation. It provides unique insights into the aspect of reproductive genetics and early human development, but has also raised important new ethical issues about assisted human reproduction. Preimplantation genetic diagnosis (PGD) is widely utilized in case of reproductive failures such as failed implantation, major birth anomalies, and miscarriages.

PGDs for aneuploidy is expected to a mainstay in the market

Aneuploidy is referred as a presence of an abnormal number of chromosomes in a cell. To examine this situation, a specific test is performed named p[reimplantation genetic testing for aneuploidies (PGT-A). the demand for PGT-A is rising owing to increased implantation rates, increased live birth rates, and less miscarriage rates. These factors further contribute to the overall growth of the global preimplantation diagnosis market.

Growing demand for early detection of genetic disorders to drive market

The overall genetic diagnosis market is majorly driven by the increasing demand for diagnosis of genetic disorders, reducing cost of IVF treatments & genetic sequencing, and non-invasive biopsy procedure. Furthermore, rising awareness related to the incidence and prevention of genetic disorders and high risk of chromosomal abnormalities in the recent generation are further boosting the global preimplantation diagnosis market. However, stringent government rules and regulations related to genetic diagnosis of the embryo along with fear of safety and privacy of genetic data may hamper the growth of this market.

North America is likely to remain the largest regional market across the world

On the basis of regional demarcation, preimplantation genetic diagnosis market is classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Rising demand from fertility clinics and adoption of novel technologies in preimplantation diagnostic techniques are driving the growth of preimplantation genetic diagnosis market in North America

Asia Pacific is likely to be the fastest-growing market for preimplantation genetic diagnosis owing to increasing investment in preimplantation consultation and testing. However, stringent government regulations and high cost of diagnostic procedures are factors expected to hamper the preimplantation genetic diagnosis market.

Key Market Players

• Reprogenetics, LLC
• Genea Limited
• Illumina, Inc.
• Natera, Inc.
• Genesis Genetics Ltd.
• PerkinElmer Inc.
• CooperSurgical, Inc.
• Yikon Genomics Co., Ltd
• Laboratory Corporation of America Holdings.
• Invitae Corporation.

Key Segment Of The preimplantation genetic diagnosis market

by Procedure, 2022-2030 (USD Million)            
    •    Preimplantation Genetic Diagnosis (Pgd)
    •    Preimplantation Genetic Screening (Pgs) Beta Thalassemia
By Type, 2022-2030 (USD Million)
    •    Chromosomal Abnormalities
    •    X Linked Diseases
    •    Embryo Testing
    •    Aneuploidy Screening
By Application, 2022-2030 (USD Million)
    •    Embryo Hla Typing For Stem Cell Therapy
    •    Ivf Prognosis
    •    Late Onset Genetic Disorders
    •    Inherited Genetic Disease
by Technology, 2022-2030 (USD Million)
    •    Next Generation Sequencing
    •    Polymerase Chain Reaction
    •    Fluorescence In Situ Hybridization
by End User, 2022-2030 (USD Million)
    •    Maternity Centers & Fertility Clinics
    •    Hospitals
    •    Diagnostic Labs
Regional Overview, 2022-2030 (USD Million)
    North America
      •    US
      •    Canada
    Europe
      •    Germany
      •    France
      •    UK
      •    Rest of Europe
    Asia Pacific
      •    China
      •    India
      •    Japan
      •    Rest of Asia Pacific
    South America
      •    Mexico
      •    Brazil
      •    Rest of South America
    Middle East and South Africa